A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

A Phase I/IIa Study on Dose-escalation and Extension of Recombinant Humanized Type II CD20 Monoclonal Antibody MIL62 Injection Combined With BTK Inhibitor Orelabrutinib in the Treatment of Recurrent/Refractory CD20+B-cell Lymphoma

Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma

Study Overview

• Status: Active, not recruiting
• Conditions: B-cell Lymphoma Refractory; B-cell Lymphoma Recurrent
• Intervention / Treatment: Drug: Orelabrutinib; Drug: Recombinant humanized monoclonal antibody MIL62 injection

• Study Type: Interventional
• Enrollment (Actual): 43
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• China
  • Anhui
    • Bengbu, Anhui, China, 100000
      • The First Affiliated Hospital of Bengbu Medical college
  • Beijing
    • Beijing, Beijing, China, 100000
      • Beijing Hospital
    • Beijing, Beijing, China, 100000
      • Cancer Hospital, Chinese Academy of Medical Sciences
    • Beijing, Beijing, China, 100000
      • Beijing Shijitan Hospital, Capital Medical University
  • Hebei
    • Baoding, Hebei, China, 100000
      • Affiliated Hospital of Hebei University
  • Henan
    • Zhengzhou, Henan, China, 100000
      • Henan Tumor Hospital
  • Hunan
    • Changsha, Hunan, China, 100000
      • Hunan Cancer Hospital
  • Jiangsu
    • Suzhou, Jiangsu, China, 100000
      • First Affiliated Hospital of Soochow University
  • Jilin
    • Changchun, Jilin, China, 100000
      • The First Hospital of Jilin University
  • Tianjin
    • Tianjin, Tianjin, China, 100000
      • Tianjin People's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥18 years, gender not limited
2. Dose escalation phase: Histologically confirmed CD20 positive B-cell non-Hodgkin's lymphoma; Expansion stage: R/R NHL Or histologically diagnosed CD20 positive chronic lymphocytic leukemia/small lymphocytic lymphoma;
3. Dose escalation phase ：Patients who have received at least one treatment regimen Expansion stage：Patients who have received at least one to four treatment regimens with at least one regimen containing rituximab;
4. Eastern cancer collaboration group(ECOG) physical status score: 0-2
5. Laboratory tests performed within 7 days prior to the first acceptance of the study drug met the protocol criteria.
6. Expected survival ≥6 months
7. Sign a written informed consent.

Exclusion Criteria:

1. Expansion stage: DLBCL transformed from follicular lymphoma, DLBCL with follicular lymphoma, and lymphomas with primary or central nervous system involvement.
2. Received any of the anti-tumor treatments(note in the protocol) before the first study drug.
3. Previous use of any anticancer vaccine.
4. Patients who had received hematopoietic stem cell transplantation within 3 months before the first administration
5. Patients scheduled for major surgery within 28 days prior to initial administration or during the expected study period.
6. Patients who Is participating in other clinical trials or first administration less than 28 days after the end of the previous clinical trial.
7. Receiving prednisone treatment or other corticosteroid treatment with the same dose as prednisone ;Patients who require warfarin or an equivalent vitamin K antagonist;
8. During the study period, drugs with moderate or severe inhibition or strong induction of cytochrome CYP3A4 were taken together;
9. Subject has a history of any of the diseases note in the protocol;
10. Patients with infections;
11. Impact testing scheme compliance or other serious results explain the poor control of the merger of the disease(note in the protocol);
12. Toxicity of any previous anticancer treatment has not recovered to ≤1, except for hair loss;
13. A history of severe allergic reactions to humanized monoclonal antibodies or known allergies to any component of Orelabrutinib or MIL62;
14. Inability to swallow research drugs, or the presence of conditions that significantly affect gastrointestinal function;
15. Hepatitis b surface antigen (HBsAg) and/or hepatitis b core antibody (HBcAb) are positive ; Hepatitis c virus (HCV) antibody positive and HCV RNA positive patients; Human immunodeficiency virus (HIV) serum response was positive;
16. Pregnant and lactating women; For women of childbearing age who have not undergone sterilization surgery: do not agree to use appropriate methods of contraception;
17. For men not undergoing sterilization: do not agree to use the barrier method of contraception;
18. Other circumstances considered inappropriate for the study by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single Arm	Drug: Orelabrutinib; BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.; Drug: Recombinant humanized monoclonal antibody MIL62 injection; Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose limiting toxicity (DLT)(Dose escalation phase)	Safety observation indicator	At the end of Cycle 1 (each cycle is 28 days)
Maximum tolerated dose (MTD) (Dose escalation phase)	Safety observation indicator	At the end of Cycle 1 (each cycle is 28 days)
Recommended dose for phase 2 trials of two-drug combinations (RP2D) (Dose escalation phase)	Safety observation indicator	At the end of Cycle 1 (each cycle is 28 days)
objective remission rate(ORR) (Dose expansion phase)	Efficacy observation indicator	At the end of Cycle 30 (each cycle is 28 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
objective remission rate(ORR)	Efficacy observation indicator	At the end of Cycle 30 (each cycle is 28 days)
Area under the plasma concentration vs time curve(AUC)	pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment	At the end of Cycle 6 (each cycle is 28 days)
Apparent half-life for designated elimination phases (t½)	pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment	At the end of Cycle 6 (each cycle is 28 days)
The peak plasma concentration (Cmax)	pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment	At the end of Cycle 6 (each cycle is 28 days)
Duration of remission(DOR)	Efficacy observation indicator	3 years after first treatment
Progression-free survival(PFS) in the treatment of R/R CD20+B cell lymphoma	Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of relapsed/refractory CD20+B cell lymphoma with 3-year progression-free survival	3 years after first treatment
overall survival(OS) in the treatment of R/R CD20+B cell lymphoma	Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma with 3-year overall survival	3 years after first treatment
Duration of remission(DOR) in the treatment of R/R NHL	Preliminary evaluation of remission duration of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma	3 years after first treatment
Progression-free survival(PFS) in the treatment of R/R NHL	Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year progression-free survival	3 years after first treatment
overall survival(OS) in the treatment of R/R NHL	Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year overall survival	3 years after first treatment

Collaborators and Investigators

• Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
• Investigators: Principal Investigator: Yuankai Shi, PhD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study record dates

Study Major Dates

• Study Start (Actual): July 28, 2020
• Primary Completion (Estimated): December 30, 2025
• Study Completion (Estimated): December 30, 2025

Study Registration Dates

• First Submitted: March 5, 2020
• First Submitted That Met QC Criteria: March 9, 2020
• First Posted (Actual): March 11, 2020

Study Record Updates

• Last Update Posted (Actual): February 7, 2024
• Last Update Submitted That Met QC Criteria: February 5, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: CD20+
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, B-Cell; Physiological Effects of Drugs; Immunologic Factors; Antibodies; Antibodies, Monoclonal
• Other Study ID Numbers: MIL62-CT03

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No